India's Richest People 2026 edition · 1 director · Source: Hurun India
- #70 B Parthasaradhi Reddy & family ₹39,400 Cr
Revenue · FY 2026
₹2,773.88 Cr
▼ 15% YoY
Net profit · FY 2026
₹141.54 Cr
Net margin 5.1%
EBITDA · FY 2026
₹326.2 Cr
EBITDA margin 11.8%
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹3.45 Cr
Issued & subscribed
Open charges
₹954.5 Cr
Satisfied ₹3,713.38 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
2,044
Provident fund records
About Hetero Drugs Limited
Data last updated:
Hetero Drugs Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 06 April 1993 and has been in existence for over 33 years.
Its director B Parthasaradhi Reddy and family are #70 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24230TG1993PLC015582. Its GSTIN is 36AAACH5071K1ZI (Telangana). The company holds 13 GST registrations, of which 7 are active.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹3.45 Cr. It was formerly known as Hetero Drugs Private Limited. It is led by directors including Sambi Reddy Jonnala (Whole-Time Director) and Adi Sesha Giri Jagarapu.
Its last annual general meeting (AGM) was held on 21 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Hyderabad, Telangana.
As per the financials filed for FY 2026, the company reported a revenue of ₹2,773.88 Cr, a decline of 15% compared to the previous year. For the same year it recorded a net profit of ₹141.54 Cr (net margin 5.1%) and EBITDA of ₹326.2 Cr (EBITDA margin 11.8%). Revenue has declined at a compounded annual rate (CAGR) of 5% over three years and 1% over five years.
The company has about 2,044 employees on its provident fund (EPFO) records. Its group structure includes 5 subsidiaries.
The company is associated with 2 brands: Hetero Group and Hetero. As per MCA filings, the company has open charges of ₹954.5 Cr and satisfied charges of ₹3,713.38 Cr on record. Court records list 273 cases involving the company, including 163 filed by the company and 110 filed against it; 41 cases are pending. The company has 7 deals on record (7 secondary share transfers); the latest was in December 2017. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 4 larger and 4 smaller; the largest is Usv Private Limited with revenue of ₹5,202.13 Cr. The company has 15 MSME Form 1 returns on record between 2019 and 2024, listing 649 overdue payments to 105 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hetero.com.
Company details
CIN U24230TG1993PLC015582
Registration Number 015582
Incorporation Date 06 April 1993
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant
CIN history
Hetero Drugs has one previous CIN (Corporate Identification Number): U24230AP1993PLC015582. The current CIN is U24230TG1993PLC015582, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230TG1993PLC015582 | Current |
| U24230AP1993PLC015582 | Previous |
Key People
Sambi Reddy Jonnala Whole-Time Director Adi Sesha Giri Jagarapu Director Kalavathi Bandi Director Recognitions & Rankings of Hetero Drugs
Contact details
Hetero Drugs Limited's registered office is in Hyderabad, Telangana. Its website is hetero.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address#7 – 2 – A2 Industrial Estate, Sanathnagar, Hyderabad, Telangana, India – 500018
- IndustryPharma, API Manufacturers
To see the full contact details of Hetero Drugs Limited, buy the company report.
Comprehensive company report
Hetero Drugs Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Hetero Drugs operates two associated brands: Hetero Group and Hetero. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| API, biosimilars and generic formulations manufacturing company. | heteroworld.com | |
| Hetero is recognized as a leading global pharmaceutical company based in India. | hetero.com |
Business activity
The main business activity of Hetero Drugs is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Hetero Drugs Limited, buy the company report.
Financials of Hetero Drugs Limited
FY 2026 filings availableHetero Drugs Limited reported revenue of ₹2,773.88 Cr (down 15% YoY) for FY 2026.
Revenue · FY 2026
₹2,773.88 Cr ▼ 15%
Net profit · FY 2026
₹141.54 Cr margin 5.1%
EBITDA · FY 2026
₹326.2 Cr margin 11.8%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 15%
3 years · compounded
▼ 5%
5 years · compounded
▼ 1%
EBITDA CAGR growth
1 year
▼ 4%
3 years · compounded
▲ 15%
5 years · compounded
▼ 4%
Revenue has declined at a compounded annual rate (CAGR) of 1% over five years, including a 15% fall in the latest year. EBITDA fell 4% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹2,773.88 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹326.2 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹141.54 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.8% | ||||
| Net Profit Margin | 5.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Hetero Drugs Limited, buy the company report.
Board of directors of Hetero Drugs Limited
Hetero Drugs has 7 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
Showing 6 of 7 current directors. View all directors
Peer comparison
Hetero Drugs Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Usv Private Limited | ₹5,202.13 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Granules India Limited | ₹4,494.53 Cr (FY 2025) | 0.0% | Hyderabad, Telangana, India | |||
| Matrix Pharmacorp Private Limited | ₹4,422.21 Cr (FY 2025) | 16378466.0% | Sangareddy, Telangana, India | |||
| Cadila Pharmaceuticals Limited | ₹3,869.17 Cr (FY 2025) | 4.0% | Ahmedabad, Gujarat, India | |||
| Hetero Drugs Limitedthis company | ₹2,773.88 Cr (FY 2026) | ₹141.54 Cr | 5.1% | -15.0% | 2,044 | Hyderabad, Telangana, India |
| Dishman Carbogen Amcis Limited | ₹2,733.18 Cr (FY 2025) | 3.0% | Ahmedabad, Gujarat, India | |||
| Covalent Laboratories Private Limited | ₹2,693.24 Cr (FY 2025) | -8.0% | Hyderabad, Telangana, India | |||
| Honour Lab Limited | ₹2,482.63 Cr (FY 2025) | 4.0% | Hyderabad, Telangana, India | |||
| Alivus Life Sciences Limited | ₹2,421.45 Cr (FY 2025) | 5.0% | Solapur, Maharashtra, India |
To see the full peer comparison of Hetero Drugs Limited, buy the company report.
Auditor
Hetero Drugs Limited is audited by Suryanarayana Reddy & Co. for the financial year 2026.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Suryanarayana Reddy & Co. | FY 2026 | 005752 S |
Shareholding
The shareholding of Hetero Drugs Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Hetero Drugs Limited, buy the company report.
Charges & borrowings
Open charges
₹954.5 Cr
Satisfied charges
₹3,713.38 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 04 Sep 2025 | 101163367 | Bank of India | ₹10.5 Lakh | Open | |
| 04 Sep 2025 | 101163398 | Bank of India | ₹14 Lakh | Open | |
| 01 Sep 2025 | 101156685 | Bank of India | ₹8 Lakh | Open | |
| 22 Aug 2025 | 101156680 | Bank of India | ₹14.88 Lakh | Open | |
| 29 Jul 2025 | 101145830 | Bank of India | ₹9 Lakh | Open |
To see the full charge records of Hetero Drugs Limited, buy the company report.
Total charge records: 72 View all charges
Deals & funding
Hetero Drugs Limited has 7 deals on record (7 secondary share transfers); the latest was in December 2017.
Total deals
7
Secondary share transfers
7
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2017 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Sep 2017 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jan 2015 | Secondary share transfer | Undisclosed | Buyer: M Krishna Sindhuri Private Trust Seller: 2 individuals |
| Nov 2014 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| Sep 2014 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: an individual |
To see the full deal history of Hetero Drugs Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Hetero Drugs Limited has 273 court cases on record: 163 filed by Hetero Drugs, 110 filed against it. 41 cases are pending and 232 are disposed.
Total cases
273
Filed by the company
163
Filed against the company
110
Pending
41
Disposed
232
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 140 | 20 | 20 |
| High courts | 126 | 88 | 20 |
| Supreme Court | 6 | 2 | 1 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 273)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Revision petition | Filed against the company by M/S.Hetero Labs Limited | Pending |
| District court, Hyderabad Central, Telangana | Court case (CC - NI) | Filed by the company against M/S Swisindia Infrastructures Pvt Ltd. Rep by Nageli Thirupalappa Chowdary | Pending |
| High Court, TELANGANA | Court case (CCCA) | Filed against the company by M/S Agarwal Foundries Pvt Ltd | Pending |
| High Court, TELANGANA | Writ petition | Filed by the company against Southern Power Distribution Company of Telangana Ltd. and 5 others | Pending |
| High Court of Andhra Pradesh | Writ petition | Filed against the company by M/S. Hetero Labs Limited | Disposed |
To see the full case history of Hetero Drugs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Hetero Drugs Limited was last rated by Care on 07 Dec 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 07 Dec 2021 |
To see the full credit ratings and regulatory alerts of Hetero Drugs Limited, buy the company report.
MSME payment delays
Hetero Drugs Limited has 15 MSME Form 1 returns on record between 2019 and 2024, listing 649 overdue payments to 105 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 105)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| BCD Travel India Private Limited | |||
| Sunlit Elements Private Limited | |||
| Mysore Ammonia and Chemicals Limited | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Hetero Drugs Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Hetero Drugs has 5 subsidiary companies and 3 associated companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
5
Subsidiary companies
3
Associated companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Valary Lab Private Limited | U24100TG2019PTC136348 | |
| Shadri Labs Private Limited | U24110TG2020PTC142045 | |
| Sicopa Lab Private Limited | U24299TG2019PTC136404 | |
| Vibhavari Industries Limited | U24304TG2017PLC117884 | |
| Asphar Research Labs Private Limited | U24304TG2017PTC117269 |
To see the full group structure of Hetero Drugs Limited, buy the company report.
Employees & EPFO
Hetero Drugs Limited has a workforce of 2,044 employees on its EPFO records as of May 2026, across 3 active EPFO establishments.
Employee count
2,044
Active EPFO establishments
3
Employee growth
2.6%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 2,044 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Hetero Drugs Limited, buy the company report.
GST
Hetero Drugs has 13 GST registrations: 7 active and 6 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
13
Active
7
Cancelled / inactive
6
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAACH5071K1ZI | Telangana | Active | 01 Jul 2017 |
| 36AAACH5071K2ZH | Telangana | Active | 06 Jul 2017 |
| 36AAACH5071K3ZG | Telangana | Active | 18 Aug 2017 |
| 27AAACH5071K1ZH | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Hetero Drugs Limited, buy the company report.
Recent activity
Hetero Drugs Limited has 33 board changes on record since 1993: 20 appointments and 13 cessations. The latest: Rathnakar Reddy Kura ceased to be Director on 25 Sep 2025.
AGM
Hetero Drugs Limited last Annual general meeting of members was held on 21 Sep 2026 as per latest MCA records.
Filing
Hetero Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Ceased
Rathnakar Reddy Kura ceased to be Director.
Charges
A charge with Bank Of India amounted to Rs. 0.11 Cr with Charge ID 101163367 was registered on 04 Sep 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.14 Cr with Charge ID 101163398 was registered on 04 Sep 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.08 Cr with Charge ID 101156685 was registered on 01 Sep 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.15 Cr with Charge ID 101156680 was registered on 22 Aug 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.09 Cr with Charge ID 101145830 was registered on 29 Jul 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.09 Cr with Charge ID 101152413 was registered on 29 Jul 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.13 Cr with Charge ID 101143949 was registered on 25 Jul 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.14 Cr with Charge ID 101143955 was registered on 25 Jul 2025.
Charges
A charge with Bank Of India amounted to Rs. 0.11 Cr with Charge ID 101143939 was registered on 21 Jul 2025.
164 earlier events are in the company report.
News
Frequently asked questions
Hetero Drugs is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 06 April 1993 (33+ years old) and is registered under CIN U24230TG1993PLC015582.
Hetero Drugs has 7 current directors:
- Sambi Reddy Jonnala - Whole-Time Director
- Adi Sesha Giri Jagarapu - Director
- Kalavathi Bandi - Director
- Venkatanarasa Reddy Attunuri - Director
- Parthasaradhi Reddy Bandi - Director
- Bandi Vamsikrishna - Director
- Gopal Reddy Annareddy - Director
The latest financial statements of Hetero Drugs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 21 September 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Hetero Drugs is 36AAACH5071K1ZI, registered in Telangana. The company has 13 GST registrations in all, of which 7 are active and 6 are cancelled or inactive. Other active GSTINs include 36AAACH5071K2ZH (Telangana), 36AAACH5071K3ZG (Telangana), 27AAACH5071K1ZH (Maharashtra).
The CIN (Corporate Identification Number) of Hetero Drugs is U24230TG1993PLC015582. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Hetero Drugs has 273 court cases on record: 163 filed by the company and 110 filed against it. 41 are pending. Most are in the district courts.
Hetero Drugs was incorporated on 06 April 1993, making it 33+ years old. It is registered with the Registrar of Companies, Hyderabad.
Hetero Drugs has 7 deals on record (7 secondary share transfers); the latest was in December 2017.
The peers of Hetero Drugs by revenue are Usv Private Limited, Granules India Limited, Matrix Pharmacorp Private Limited, Cadila Pharmaceuticals Limited, Dishman Carbogen Amcis Limited and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).
Rathnakar Reddy Kura ceased to be Director on 25 Sep 2025. Chetan Kumar Sharma ceased to be Company Secretary on 02 Jul 2025. Chetan Kumar Sharma was appointed as Company Secretary on 03 Feb 2025. Hetero Drugs has 33 board changes on record in total.
Hetero Drugs has 15 MSME Form 1 returns on record between 2019 and 2024, listing 649 overdue payments to 105 micro and small suppliers. The latest return was filed on 02 May 2024.
Hetero Drugs can be reached through the website hetero.com. Its registered office is in Hyderabad, Telangana, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages